Medarex

Medarex, Inc. (formerly NASDAQ: MEDX) was a biopharmaceutical company focused on the discovery, development, and commercialization of fully human antibody-based therapeutics to treat life-threatening diseases. Its primary technology platforms included UltiMAb Human Antibody Development System and Bispecific Antibody technologies.

Medarex's UltiMAb platform was used to generate fully human antibodies targeting a variety of disease targets. These antibodies were designed to mimic the natural human immune response and offer potential advantages over traditional monoclonal antibodies derived from animal sources.

The company was also a pioneer in the field of bispecific antibodies, developing technologies to create antibodies that can bind to two different targets simultaneously. This approach allowed for the development of therapeutic agents with multiple mechanisms of action, potentially enhancing their efficacy.

Medarex collaborated with numerous pharmaceutical and biotechnology companies to develop and commercialize its antibody-based therapies. Key collaborations included partnerships for the development of antibodies in the areas of oncology, immunology, and infectious diseases.

In 2009, Medarex was acquired by Bristol-Myers Squibb for approximately $2.4 billion. The acquisition provided Bristol-Myers Squibb with access to Medarex's antibody technology platforms and its pipeline of antibody-based therapeutics, particularly in the field of immuno-oncology. The acquisition of Medarex played a significant role in Bristol-Myers Squibb's subsequent success in developing and commercializing immuno-oncology therapies.